NSF selects 34 semifinalists for the inaugural NSF Regional Innovation Engines competition

NSF announces the list of semifinalists to transparently encourage teaming, diversity and regional growth

The U.S. National Science Foundation announced 34 semifinalists for the first-ever NSF Regional Innovation Engines (NSF Engines) competition, spanning nearly all key technology areas and societal and economic challenges highlighted in the “ CHIPS and Science Act.” The NSF Engines will be led by universities, nonprofits, businesses and other organizations from across U.S. states and territories. NSF is releasing the list of semifinalists to transparently encourage teaming among diverse organizations, innovation, and regional growth. View details and a  map of the NSF Engines semifinalists  on the NSF website.

The NSF Engines program is anticipated to be transformational for the nation, ensuring the U.S. remains globally competitive in key technology areas for decades to come. Each NSF Engine could receive up to $160 million over 10 years; actual amounts will be subject to a given NSF Engine’s status and overall progress, as assessed annually. NSF anticipates announcing the final list of NSF Engines awards this fall, with each awardee initially receiving about $15 million for the first two years.

“Each of these NSF Engines semifinalists represents an emerging hub of innovation and lends their talents and resources to form the fabric of NSF’s vision to create opportunities everywhere and enable innovation anywhere,” said NSF Director Sethuraman Panchanathan. “These teams will spring ideas, talent, pathways and resources to create vibrant innovation ecosystems all across our nation.”

NSF initially received  188 concept outlines for NSF Engines.  Following a proposers’ day and other activities that encouraged teaming, NSF has now completed initial merit review of proposals, narrowing to the 34 semifinalists .  During the next stage, NSF will interview each team to assess their proposed leadership’s ability to rapidly mobilize in the first two years; their competitive advantages; and budget and resources for their planned research and development, translation and workforce development efforts. Those selected to move to the final round in July will be interviewed in person to assess risks and committed resources, as well as the team’s ability to adapt to changing circumstances.

Semifinalists not selected to receive an NSF Engine award may be considered for an NSF Engine Development Award of up to $1 million over two years. These planning awards will help teams build their initial ecosystems, cultivate the necessary partnerships and potentially compete for additional funding, including through future NSF Engines competitions. Learn more about the review process by reading the  funding opportunity.

Launched by NSF’s new Directorate for Technology, Innovation and Partnerships (TIP) and authorized by the “CHIPS and Science Act,” the NSF Engines program uniquely harnesses the nation’s science and technology research and development enterprise and regional-level resources. NSF Engines aspire to catalyze robust partnerships to positively impact the economy within a geographic region, address societal challenges, advance national competitiveness and create local, high-wage jobs across the country.

“Today’s announcement builds upon the  44 NSF Engines Development Awards  that we announced in early May,” noted Erwin Gianchandani, NSF assistant director for TIP. “Over the next two years, those awards will help organizations create connections and develop their local innovation ecosystems to prepare strong proposals for becoming future NSF Engines. Collectively, the NSF Engines Development Awards and today’s NSF Engines semifinalists will ensure the U.S. harnesses the geography of innovation and remains in the vanguard of competitiveness well into the future.”

More information about the NSF Engines program can be found on the  NSF Engines program website.

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS